STO · NANEXA.ST
Nanexa AB (publ)
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
Loading market information…
STO · ELIC.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Elicera Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 60.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Elicera Therapeutics AB (publ)’s next earnings report is currently expected on Nov 27, 2026, with estimated earnings per share of -SEK 0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elicera Therapeutics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 233.63K |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
SEK 5.17-SEK 0.17 (-3.18%)
Mendus AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.1% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 0.78-SEK 0.00 (-0.64%)
Intervacc AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
SEK 0.18-SEK 0.00 (-1.85%)
Acarix AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 47.69% below the high.
SEK 2.09+SEK 0.04 (+1.95%)
Initiator Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 42.74% below the high.
SEK 0.16+SEK 0.00 (+2.61%)
Xintela AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 67.32% below the high.
SEK 0.58+SEK 0.06 (+12.62%)
Ascelia Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 83.66% below the high.
